Corrigendum to "A double-regulated oncolytic adenovirus with improved safety for adenocarcinoma therapy" [Biochem. Biophys. Res. Commun. 388 (2009) 234-239] (DOI:10.1016/j.bbrc.2009.07.142);A double-regulated oncolytic adenovirus with improved safety for adenocarcinoma therapy

Biochemical and Biophysical Research Communications

Volumn 388, Issue 2, 2009, Pages 234-239

  Wei, Na ^a   Fan, Jun Kai ^a   Gu, Jin Fa ^a   He, Ling Feng ^a,b   Tang, Wen Hao ^c   Cao, Xin ^a   Liu, Xin Yuan ^a,d  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c FUDAN UNIVERSITY   (China)

^d ZHEJIANG SCI TECH UNIVERSITY   (China)

Author keywords

MUC1 promoter; Oncolytic adenovirus; Replication specificity; Safety

Indexed keywords

E1A PROTEIN; MUCIN 1; MUD 55; ONCOLYTIC ADENOVIRUS; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG MEGADOSE; EMBRYO; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER TOXICITY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROGENY; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENE;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 69249205378     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.04.121     Document Type: Erratum

References (17)

1. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J.A., Sampson-Johannes A., Fattaey A., and McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274 (1996) 373-376
2. Kirn D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin. Biol. Ther. 1 (2001) 525-538
3. Zhang Z.L., Zou W.G., Luo C.X., Li B.H., Wang J.H., Sun L.Y., Qian Q.J., and Liu X.Y. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res. 13 (2003) 481-489
4. Rodriguez R., Schuur E.R., Lim H.Y., Henderson G.A., Simons J.W., and Henderson D.R. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57 (1997) 2559-2563
5. Tsukuda K., Wiewrodt R., Molnar-Kimber K., Jovanovic V.P., and Amin K.M. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res. 62 (2002) 3438-3447
6. Girling A., Bartkova J., Burchell J., Gendler S., Gillett C., and Taylor-Papadimitriou J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int. J. Cancer 43 (1989) 1072-1076
7. Burdick M.D., Harris A., Reid C.J., Iwamura T., and Hollingsworth M.A. Oligosaccharides expressed on MUC1 produced by pancreatic and colon tumor cell lines. J. Biol. Chem. 272 (1997) 24198-24202
8. Kovarik A., Peat N., Wilson D., Gendler S.J., and Taylor-Papadimitriou J. Analysis of the tissue-specific promoter of the MUC1 gene. J. Biol. Chem. 268 (1993) 9917-9926
9. Chen L., Chen D., Manome Y., Dong Y., Fine H.A., and Kufe D.W. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J. Clin. Invest. 96 (1995) 2775-2782
10. Abe M., and Kufe D. Transcriptional regulation of DF3 gene expression in human MCF-7 breast carcinoma cells. J. Cell. Physiol. 143 (1990) 226-231
11. Steegenga W.T., Riteco N., Jochemsen A.G., Fallaux F.J., and Bos J.L. The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells. Oncogene 16 (1998) 349-357
12. O'Shea C.C., Johnson L., Bagus B., Choi S., Nicholas C., Shen A., Boyle L., Pandey K., Soria C., Kunich J., Shen Y., Habets G., Ginzinger D., and McCormick F. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 6 (2004) 611-623
13. O'Shea C.C., Soria C., Bagus B., and McCormick F. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell. 8 (2005) 61-74
14. Gallimore P.H., and Turnell A.S. Adenovirus E1A: remodelling the host cell, a life or death experience. Oncogene 20 (2001) 7824-7835
15. Mymryk J.S., and Bayley S.T. Multiple pathways for gene activation in rodent cells by the smaller adenovirus 5 E1A protein and their relevance to growth and transformation. J. Gen. Virol. 74 Pt. 10 (1993) 2131-2141
16. Zou W., Luo C., Zhang Z., Liu J., Gu J., Pei Z., Qian C., and Liu X. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene 23 (2004) 457-464
17. Kurihara T., Brough D.E., Kovesdi I., and Kufe D.W. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Invest. 106 (2000) 763-771